Q3 EPS Estimate for Quest Diagnostics Increased by Analyst

Quest Diagnostics Incorporated (NYSE:DGX) – Stock analysts at William Blair raised their Q3 2025 earnings per share estimates for Quest Diagnostics in a research note issued on Tuesday, April 22nd. William Blair analyst A. Brackmann now anticipates that the medical research company will post earnings per share of $2.51 for the quarter, up from their previous estimate of $2.50. The consensus estimate for Quest Diagnostics’ current full-year earnings is $9.70 per share. William Blair also issued estimates for Quest Diagnostics’ Q4 2025 earnings at $2.40 EPS, Q1 2026 earnings at $2.36 EPS, Q2 2026 earnings at $2.93 EPS, Q3 2026 earnings at $2.73 EPS, Q4 2026 earnings at $2.48 EPS and FY2026 earnings at $10.50 EPS.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Tuesday, April 22nd. The medical research company reported $2.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.15 by $0.06. Quest Diagnostics had a net margin of 8.80% and a return on equity of 15.07%. The business had revenue of $2.65 billion for the quarter, compared to the consensus estimate of $2.63 billion.

Other analysts have also issued research reports about the company. Citigroup lowered Quest Diagnostics from a “buy” rating to a “neutral” rating and set a $185.00 price objective on the stock. in a report on Tuesday, March 4th. Barclays lifted their price target on shares of Quest Diagnostics from $175.00 to $185.00 and gave the stock an “equal weight” rating in a research note on Wednesday. StockNews.com cut shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Thursday, February 6th. Leerink Partners upgraded shares of Quest Diagnostics from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $169.00 to $174.00 in a research report on Monday, January 6th. Finally, Evercore ISI increased their price target on shares of Quest Diagnostics from $175.00 to $180.00 and gave the stock an “in-line” rating in a research report on Wednesday. Eight analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $183.73.

Quest Diagnostics Stock Up 1.4 %

DGX stock opened at $175.92 on Thursday. Quest Diagnostics has a twelve month low of $134.05 and a twelve month high of $178.87. The company has a quick ratio of 1.02, a current ratio of 1.10 and a debt-to-equity ratio of 0.82. The company has a market cap of $19.63 billion, a PE ratio of 22.88, a price-to-earnings-growth ratio of 2.16 and a beta of 0.78. The business’s 50-day simple moving average is $168.88 and its 200 day simple moving average is $160.81.

Institutional Investors Weigh In On Quest Diagnostics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD raised its holdings in Quest Diagnostics by 42.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,490,278 shares of the medical research company’s stock worth $828,265,000 after purchasing an additional 1,637,525 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Quest Diagnostics by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 2,690,021 shares of the medical research company’s stock worth $404,764,000 after buying an additional 73,368 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Quest Diagnostics by 60.4% during the fourth quarter. JPMorgan Chase & Co. now owns 2,433,913 shares of the medical research company’s stock worth $367,180,000 after buying an additional 916,898 shares during the last quarter. Grantham Mayo Van Otterloo & Co. LLC lifted its holdings in Quest Diagnostics by 1.2% in the fourth quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 2,268,990 shares of the medical research company’s stock valued at $342,300,000 after buying an additional 26,214 shares during the period. Finally, Norges Bank bought a new position in Quest Diagnostics in the fourth quarter valued at approximately $191,823,000. Institutional investors own 88.06% of the company’s stock.

Insider Activity at Quest Diagnostics

In related news, Director Vicky B. Gregg sold 1,250 shares of the firm’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $164.57, for a total value of $205,712.50. Following the completion of the sale, the director now owns 16,867 shares of the company’s stock, valued at $2,775,802.19. This trade represents a 6.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO J. E. Davis sold 39,191 shares of the company’s stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $168.46, for a total value of $6,602,115.86. Following the transaction, the chief executive officer now directly owns 127,623 shares in the company, valued at approximately $21,499,370.58. This represents a 23.49 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 55,903 shares of company stock valued at $9,460,221 over the last ninety days. 8.16% of the stock is owned by insiders.

Quest Diagnostics Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 21st. Stockholders of record on Monday, April 7th were paid a $0.80 dividend. The ex-dividend date of this dividend was Monday, April 7th. This is a positive change from Quest Diagnostics’s previous quarterly dividend of $0.75. This represents a $3.20 dividend on an annualized basis and a dividend yield of 1.82%. Quest Diagnostics’s dividend payout ratio (DPR) is 40.46%.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.